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Summary Rasmussen encephalitis (RE) is a severe and progressive focal epilepsy of
unknown origin that leads to deterioration of motor and cognitive function. In a
previous study, we described positive effect of high doses of steroids during the first
year after the onset of RE. The objective of this study was to evaluate this therapy at
long term.
We reviewed 11 patients (7 girls and 4 boys) with RE of the right hemisphere (7) and
the left (4) at a follow-up of 9  2 years. Age at onset of RE ranged from 2 to 14 years.
Six patients had no benefit from steroid therapy and underwent hemispherotomy.
Five had significant reduction of seizure frequency with disappearance of epilepsia
partialis continua, and improved motor function. Of these, two died of unexpected
sudden death 5 and 7 years after seizure control. Two others with initial response
experienced progressive recurrence of seizures 1 to 4 years after the end of steroid
therapy and required hemispherotomy. Finally, only one patient exhibited total
cessation of seizures with steroids for 3 years, but seizures progressively recurred
although the frequency was moderate.
Our data confirm that although steroid treatment can be useful when given early in
the course of RE, long term relapse can occur among the good responders requiring
delayed hemispheric disconnection.
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Rasmussen’s encephalitis (RE) is a chronic inflamma-
tory brain disorder leading to unilateral hemispheric
brain destruction. This process is accompanied by
progressive impairment of neurological functions. Published by Elsevier Ltd. All rights reserved.
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able seizures.1,2
Usually, a progressive course of focal onset sei-
zures, characteristically epilepsia partialis continua
(EPC)3 as well as neurological deterioration (more
often progressive motor defect) occurs. The diag-
nosis of RE is also based on neuroradiological find-
ings, with characteristic MRI features of areas of
cortical hyperintense T2/fluid attenuated inversion
recovery (FLAIR) signal and atrophy of the affected
hemisphere.4,5 Even though, clinical and radiologi-
cal finding are sufficient for diagnosis of RE, histol-
ogy is still regarded as the gold standard for
establishing the diagnosis of RE. Histopathologically,
chronic inflammation, astrogliosis and microgliosis,
neuronal loss and hemispheric atrophy are found
mainly in the cortex.1,6,7 The pathogenesis of RE has
been linked to autoimmune process including
antoantibodies8 and cytotoxic T cells.9
Although hemispherectomy/hemispherotomy
(disconnection of one hemisphere) may interrupt
the seizure activity, such an indication is only accep-
table to the patient and parents when hemiparesis
has developed. Thus, there is a need for an effective
treatment in early stages for both control of seizures
andprevention of neurological deterioration. Various
broad spectrum immunosuppressant treatments,
including corticosteroids and cyclophosphamide as
well as therapies directed primarily against humoral
immune reaction like plasmapheresis/immunoab-
sorption or intravenous immunoglobulins have been
applied with moderate success (for a review,10).
In a previous study, we proposed to treat these
patients with high dose steroids, at doses usually
given to patients with multiple sclerosis. At short
term, there was improvement of motor function in
half the patients, and favorable factors for response
to treatment comprised early administration of
high doses of steroids.11,12 We now reviewed criti-
cally the course of the disorder following steroid
therapy with a follow-up of up to 11 years (9  2
years).Patients and methods
Over the past 20 years (1983—2003), we identified
14 patients with the clinical and radiological char-
acteristics of RE, including intractable focal sei-
zures, EPC3 and progressive neurological deficit,
according to literature criteria.13 Bilateral EPC
was excluded. We also excluded the patients who
had EPC from metabolic (i.e. MERRF or Alpers dis-
ease) or viral (measles) diseases.
These RE patients were treated with high
doses steroids (including intravenous bolus and oralsteroids) as part of their treatment, including con-
ventional antiepileptic therapy. Among the 14 RE
patients, 3 patients did not respond to steroid ther-
apy within the 2 months after its introduction, since
they developed intractable epilepsy and lost the
ability to walk.12 Therefore, we also excluded these
patients and we selected the 11 remaining patients
(7 girls, 4 boys) for the present long term follow-up
study. They had unilateral EPC together with the
criteria of Rasmussen syndrome and still had the
ability to walk independently when steroid therapy
was started.
The files were studied retrospectively with a
particular emphasis given to (a) the age of onset
of first seizures as well as the seizure types, the age
of onset of epilepsia partialis continua, and the
hemisphere affected by RE; (b) the time lag
between the onset of first seizures and onset of
epilepsia partialis continua and neurological deficit
to initiation of steroid treatment; (c) the course of
epilepsia partialis continua and of neurological con-
dition, with special emphasis on walking and
speech; (d) the time lag from relapse after steroid
to surgery, and the age at surgery; (e) the course of
epilepsy and neurological deficits at 6 month steroid
therapy and (f) the course of epilepsy and neurolo-
gical deficits at the last visit.
The six month follow-up data of eight patients of
this series have been reported in a previous study.12Results
Patients characteristics (Table 1)
Clinical, EEG, and neuroimaging in the first 4
months after onset are summarized in Table 1.
Age at onset ranged from 2 to 14 years (mean
6  3.7). RE affected the right hemisphere in 7
cases and the left one in 4 cases. Disease onset
was marked in all cases by partial epileptic seizures
that constituted the first manifestation of RE: they
consisted of simple partial motor seizures in eight
cases, and of complex partial seizures in three
cases. Epilepsia partialis continua rapidly followed
in 9/11 patients, 1—30 months after the first sei-
zures (mean 9.7  11.08). Neurological deficit was
never the first manifestation of the disease. Before
steroids, nine patients had developed focal motor
deficit, involving one limb in five cases, and
consisting of hemiparesis in the 4 others. On
starting steroids, five patients were able to walk
alone. Three patients had cognitive impairment
consisting of motor aphasia (cases # 3 and # 10)
frontal behavior (case # 3), and attention deficit
(case # 5).
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Table 1 Main individual characteristics at onset
Patient/
Sex
Age of
seizure
onset (y)
Time lag between
the seizure onset
and EPC onset (m)
Seizure type CSF
oligoclonal
bands
EEG at onset
(within the first
3 months)
MRI at onset
(within the
first 6 months)
1/M 2 1 CPS motor No R centro-temporal
SW and sp
R GWA/WMA
2/M 6 24 SPS motor FS Yes R SW and sp R CA
3/M 6 5 CPS motor No L frontal sp L CA
4/F 3 1 SPS motor
atonic
Yes R fronto-temporal
SW and sp
R GWA
5/F 8 0 SPS motor
absences
No R fronto-parietal
SW and sp
R CA
6/F 3 12 SPS motor No R occipital SW and sp R CA and
GWA/WMA
7/F 9 36 SPS motor No R SW and sp R CA and
GWA/WMA
8/F 3 6 SPS motor FS No R frontal SW and sp R CA
9/M 14 1 CPS motor No L SW and sp L GWA and CA
10/M 9 3 SPS motor Yes L SW and sp L CA
11/F 3 24 SPS motor
hemitonic
No L SW and sp L CA/GWA
F: female; M:male; y: years; m:months. EPC: epilepsia partialis continua; SPS: simple partial seizures; CPS: complex partial seizures;
R: right; L: left; SW: slow waves; sp: spikes; FS Focal Spike. CA: cortical atrophy; GMA: gray matter intensity abnormalities; WMA:
white matter intensity abnormalities.Steroid treatment schedule
The steroid treatment schedule is summarized in
the Table 2. It was not exactly the same for each
patient, as four of them were referred from another
hospital. 7/11 patients received steroid therapy
consisting in a series of 3 intravenous bolus of
methylprednisolone, (400 mg/m2 of body surface)
during the first 6 days (on alternate days), repeated
2 months later, together with oral prednisone at
2 mg/kg of body weight daily. Among the four
remaining patients, three received intravenous
bolus of methylprednisolone followed by oral pre-
dnisone whereas one only received oral prednisone.Table 2 Individual steroid treatment schedule
Patient/
Sex
Time between first
symptoms and introduction
of high doses of steroids (m)
Total nu
steroid b
1/M 1 15 bolus
2/M 30 6 bolus
3/M 8 6 bolus
4/F 3 6 bolus
5 /F 4 No
6/F 12 15 bolus
7/F 12 6 bolus
8/F 12 19 bolus
9/M 7 18 bolus
10/M 1 3 bolus
11/F 36 24 bolus
F: female; M: male; y: years; m: months.Steroid treatment was started 3 months to 3
years following the first seizures (mean 10.6
months  11.7), less than 1 year in 8 cases and
before the third year of evolution for the remaining
3 cases. If seizure frequency decreased, EPC dis-
appeared and motor function recovered within the
first 2 months of steroid treatment, treatment was
maintained for 2 years, with progressive decrease of
dose of oral prednisone, bolus of prednisolone being
administered every 2months for 6 months. The total
steroid bolus ranged from 3 to 19 bolus (mean
10.7  7.7). The total steroid duration was 24.3
months 15.1, during which bolus of methylpredni-
solone lasted 7.4 months 5.4.mber of
olus
Total bolus
duration (m)
Total steroid
treatment (IV + oral)
duration (months)
13 17
10 No
3 3
3 3
29
12 21
3 15
11 48
12 24
1 22
14 17
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Table 3 Short and long-term course on steroids
Patient/
age (y)
Just before treatment RE course between 2 and 6 months Long term course
Epilepsy/EPC Deficit Epilepsy/Seizure
reduction (%)
Deficit motor/
behavioral recovery
Time lag
introduction of
steroids — relapse
Epilepsy Deficit Steroid
treatment
duration (m)
1/12 LUL (EPC) L H did not walk <50 Partial; walks with
assistance
4 m Relapse L UL L UL frontal
behavior
17
2/15 LH (EPC) LH; walks with
assistance
90 No improvement 3 m Relapse L UL + face L H walks unstable No
3/14 RUL (EPC) RH motor aphasia;
did not walk
90 Partial; walks alone 7 m Relapse RUL RH walks with
assistance frontal
behaviour
3
4/11 LUL (EPC) L H Did not walk 90 Complete 1 y Relapse RUL L H walks with
assistance
3
5/18 LH Attention deficit 90 No 3 y Relapse L H did not walk 29
6/13 LH (EPC) L H 50—90 Partial 6 m Relapse LH L H Walks with
assistance
21
7/12.5 LH No motor deficit <50 N/A 3 m LUL L UL Walks alone 15
8/16 L Foot (EPC) L Lo Walks with
assistance
90 Complete walks
alone (5 m)
4 y Relapse LH Does not walk
atonic falls
48
9/21a RH (EPC) R Lo walks with
assistance
90 Complete; Walks alone 4 m Relapse RH 24
10/16a RUL (EPC) RUL motor aphasia 90 Partial; language
improvement
2 y Relapse RUL Walks alone 22
11/14 RUL (EPC) RUL walk alone >90 Partial 3 y Relapse RUL R UL walk alone 17
y: years; m: months; EPC: epilepsia partialis continua; L: left; R: right; H: half of the body; UL: upper limb; Lo: lower limb.
a For patient 9 and 10, age of death.
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Nine patients (cases # 2, 3, 4, 5, 6, 8, 9, 10, 11) had
more than 50% reduction of seizure frequency on
steroids within the first 6 months, with eight having
at least 90% seizure reduction. Among them, three
had complete motor, but one patient (case # 2)
remained with severe motor deficit despite seizure
control. In addition, one patient (case # 5) who
exhibited neither EPC, nor permanent motor deficit
before the initiation of steroids, kept behavioral
disorders unchanged with steroids.
No severe side effects were observed. However,
all 11 patients exhibited mild to moderate steroids
related side effects. They consisted of Cushing syn-
drome in 11, osteoporosis in 3 (with fracture of the
femur in one patient), hypertension in 1, and infec-
tion in 1 (oral and vaginal candidosis).
Over 6 month follow-up–—last visit
(Table 3)
The age of the patients ranged from 11 to 18 years
(mean 13.9  2.15) at last visit. The mean follow-up
was 9  2 years. Table 3 summarizes the evolution of
the 11 patients before and after steroids.
Six patients (cases # 1, 2, 3, 4, 6, 7) experi-
enced a progressive relapse of epilepsy and EPC
between 3 and 12 months after the introduction of
steroids. These patients underwent early hemi-
spherotomy. Seizures completely disappeared
between the age of 4 and 13 years (mean
7.8  4.1). Time lag for surgery ranged from 1
to 7 years (mean 3  2.1), according to the time
lag to the development of hemiparesis and the
acceptability of the operation by the patient and
its parents (Table 4).
The five remaining patients (cases # 5, 8, 9, 10,
11) had a longer seizure remission, disappearance ofTable 4 Course after surgery
Patient/
Sex
Age at
onset (y)
Age at
surgery (y)
Current
Age (y)
1/M 2 4 12
2/M 6 13 15
3/M 6 9 14
4/F 3 4 11
5 /F 8 15 18
6/F 3 5 13
7/F 9 12 12.5
8/F 3 14 16
9/M 14 — Death
10/M 9 — Death
11/F 3 — 14
F: female; M: male; y: years; m: months.EPC, and improvedmotor function, during 2—3 years
after starting steroids protocols. However, their
evolution was still negative since:- TA
a
N
Y
Y
Y
N
N
Y
N
N
N
Nwo of them (cases # 9 and 10) died of sudden
unexpected death (SUDEP) respectively 5 and 7
years after seizure control (at the respective age
of 16 and 21 years). Both were found dead in their
bed, without evidence that a seizure was the
cause of death. Neuropathological study per-
formed in the boy showed severe hemispheric
atrophy, but no evidence of reactivation of inflam-
mation suggesting active encephalitis.- The third patient (case # 11), initially right-handed
and exhibiting EPC on the right side of the body,
underwent total cessation of seizures with steroid
therapy for 3 years. Progressively, seizures
recurred but the frequency was moderate and
did not affect the regularity of schooling, since
at the age of 12 years they still occurred only at
night. Functional MRI at that age showed that
speech was still located on the left hemisphere.- The two remaining patients with initial response
(cases # 5 and 8) later relapsed, after the end of
steroid therapy. The first one (case # 5) experi-
enced total remission of epilepsy for 3 years, but
relapsed 7 months after withdrawal of steroids.
Seizures progressively became weekly, then sev-
eral times a week with drop attacks, and then with
repeated episodes of status epilepticus. The inju-
ries produced by the drop attacks and the
repeated episodes of status epilepticus requiring
admission to hospital, precipitated the decision of
disconnection of the affected hemisphere. Right
hemispherotomy was performed at the age of 15.
On the last examination, she was 18 years old,
seizure-free since 3 years and without antiepilep-
tic drugs. She had left hemiplegia, could walk
alone and followed rehabilitation program.ED treatment withdrawn
fter surgery
Follow up
after surgery
o 8 y
es 2 y
es 5 y
es 7 y
o 3 y
o 7 y
es 6 m
o 2 y
o Sudden death at 21 y
o Sudden death at 16 y
A NA
490 N. Bahi-Buisson et al.- The second patient (case # 8) remained totally
seizure-free for 4 years. Progressively, she experi-
enced a slow and continuous relapse of RE, with
hemianopsia, progressive motor deficit leading to
left hemiparesis and recurrence of complex par-
tial seizures and atonic falls that prevented her
from walking alone. Hemispherotomy was per-
formed at the age of 14 years. She was 16 years
old at the last examination, and has been seizure-
free since 2 years without antiepileptic drugs. She
had left hemiplegia, walked alone and followed a
rehabilitation program.
The mean age of the patients with a sustained
response to steroids was 7.4 years compared to 4.8
years for the patients who relapsed before 6 months
( p < 0.02). However, we did not find any correlation
between the steroid treatment schedule and long
term outcome: the mean time passed to steroids
was respectively 10.2 months and 11 months for the
two groups of patients without any statistical dif-
ference; there was no difference between the mean
bolus steroids duration between the two groups
(12.8 months versus 9 months), although the total
duration was different with 33 months versus 17.2
months; the 8/11 patients early treated had either
no improvement or severe late relapse indepen-
dently of the steroid regimen and lag.Discussion
This retrospective study addressing the long term
evolution of RE after steroid treatment provides
interesting data about the benefits and the limits
of this therapy, and raises a number of issues.
These data suggest that steroid treatment may
benefit to half the patients from the beginning, with
recovery of motor function and good control of a
very devastating epilepsy, permitting them to
recover the ability to return to school. For the
patients who do not benefit from steroid treatment
from the beginning, surgery soon becomes an option
because the motor deficit permits disconnection of
the affected hemisphere without evidence of
further defect.14,15
However, for the patients who benefit initially,
long term benefit of steroids remains questionable.
Indeed, in some cases (2/5 in our series), steroid
response is transient with progressive seizure
relapse and the need to proceed to surgery later
in life, during adolescence, at an age at which the
disconnexion of one hemisphere is likely to be per-
ceived much more negatively.14,16
Whether progressive relapse is an expression of
steroids tolerance or a consequence of decrease ofsteroids doses remains to be determined. However,
longer steroids treatment with high doses might
contribute to more side effects than we observed
in our series. In the future, the development of new
immunomodulatory treatment, such as Tacrolimus,
might give new options for RE patients with initial
remission under steroids.
Following an initial benefit of steroids, some
patients were found dead in their beds, with no
evidence that a seizure was responsible of this out-
come. Epilepsy was under control with rare sei-
zures, no episodes of status epilepticus, and no
evidence of steroid deficiency syndrome. SUDEP
occurs more likely during sleep, and is a well iden-
tified problem for patients with epilepsy. Although
the literature suggests that SUDEP is more frequent
in patients with severe epilepsy than in the general
population, no correlation has been found with
seizure frequency suggesting that unknown clinical
indices may be important.17
By the end of the study, only one of the five
responders was still under relative control at the
age of 12 years, with rare nocturnal seizures, no
motor defect although there was some right hand
neglect. Since functional MRI showed location of
speech area on the affected left hemisphere, there
could be no indication for hemispherotomy at this
age.
As previously recommended, steroid protocols
were started less than 1 year following the first
seizures in most cases, during the acute phase of
RE that is the stage of active inflammation. In late
stages, inflammation is no longer pronounced and
irreversible tissue damage has already taken
place.5,12,18 Nevertheless, we did not find any cor-
relation between the steroid treatment schedule
and long term outcome.
Recently, the pathophysiologic concepts of RE
have evolved, giving new insight into the mechan-
isms of action of steroids in RE.10 According to this
model, the pathogenic process is initiated by a focal
event, such as a viral infection and/or other immune
mediated brain damage.19 After the disease process
has begun, MHC-1 restricted antigen presentation
and the entry of activated cytotoxic T lymphocytes
(CTLs) into the brain would lead to an attack against
neurons. The inflammatory process, including the
release of soluble mediators like cytokines, causes a
spread of the inflammatory reaction with recruit-
ment of more inflammatory cells, including
CTLs.9,20,21 The release of Granzyme B by CTLs
may cleave insufficiently glycosylated GluR3 (sub-
unit 3 of the ionotropic glutamate receptor) in a way
that gives rise to the generation of antibodies which
by themselves may lead to an antibody mediated
‘‘second way of attack’’.22,23
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doses of corticosteroids may have many mechanisms
of action that modulate both humoral and cellular
immune processes.11,12 They also have an anti-
inflammatory effect. Theymay repair thebloodbrain
barrier and as a result, could induce the decrease of
entry of activated CTLs into the CNS. Finally, corti-
costeroids have a minor anti-epileptic effect.11,12
Our data show that steroids do not give a sustained
effect on the course of childhood RE since at least 8/
11 treatedwith high doses steroids experienced short
or long term relapse. Initial results were encouraging
especially for adolescents, long term evolution with
steroid treatment resembles to the natural evolution
of the process, since after an initial silent period,
patient relapse with the same clinical feature.1,2
In the literature, two main studies report some
encouraging results of steroids on childhood RE.
Hart et al. reported 8 out of 17 patients with a
favorable response having greater than 50% reduc-
tion in seizure frequency, while 2 other patients
showed a 25% reduction in seizure frequency.13
Similarly, Chinchilla reported 7/8 positive initial
response to steroid treatment.12 The response
involved seizure reduction and improvement of
focal deficit within 6 months. Five patients experi-
enced a lasting effect although they had periodic
episodes of transient relapse with extent of EPC and
motor deficit. In this series, only 1/7 patients with
EPC had persistent long term response to steroids.
However, follow-up was very short in both series,
less than one year in Hart’s series,13 and 42 months
in average in Chinchilla’s series.12 The long term
follow-up that we present shows that the prolonged
course leads to surgery in nearly all the patients
because of later relapse of EPC.
Our findings suggest that a long term follow-up is
needed before assessing the efficacy of one drug or
one protocol in RE. Early results should be reviewed
some years later before concluding to the efficacy of
one protocol.
Given the diversity of treatment schedule in our
series and the lack of comparative data we can only
refer to the previous strategy that consists of series
of intravenous bolus of methylprednisolone
together with oral prednisone as an early treat-
ment, within the 2—6 first months of evolution.
For the long term treatment, evaluations of immu-
nomodulatory treatment are in process and might
give new perspective in the RE.Conclusion
Corticosteroids can be a useful treatment of RE,
when started in the active phase of the disease, lessthan 2 years after the first signs. However, with the
schedule we used steroid therapy did not produce
long lasting recovery. In many cases, long term
relapse can occur, leading to delayed hemispheric
disconnection. New strategies for treatment of RE
are therefore requested, for both control of seizures
and prevention of the almost inevitable neurological
deterioration.References
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